MedTrace Logo

Effects of Yeast Beta-glucan on Cognitive Function in Patients With Mild Cognitive Impairment

NCT06083350 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2024-05-14

No results posted yet for this study

Summary

Patients with mild cognitive impairment aged 50-80 years old were recruited in Shiyan City, Hubei Province, and divided into intervention group and placebo group. They were given yeast β-glucan capsules and starch capsules, respectively, for 6 months, in order to explore whether yeast β-glucan can improve cognitive function of patients with mild cognitive impairment by regulating gut microbiota and its metabolites.

Conditions

Interventions

DIETARY_SUPPLEMENT

Yeast beta-glucan

Produced by Angel Yeast Co., LTD

DIETARY_SUPPLEMENT

Starch

Produced by Angel Yeast Co., LTD

Sponsors & Collaborators

  • Xiaofan Xu

    lead OTHER

Principal Investigators

  • Xiaofan Xu, Master · School of Public Health, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2024-02-05
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083350 on ClinicalTrials.gov